Treatment of aspirin-intolerant asthma with antileukotrienes

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Dahlén, Barbro ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; DESENSITIZATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW;

EID: 0034058489     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-27     Document Type: Review

References (45)

1. Szczeklik, A., R. J. Gryglewki, and J. R. Vane. 1998. Eicosanoids, Aspirin and Asthma. Marcel Dekker, New York.
2. Stevenson, D. D., and R. A. Simon. 1988. Aspirin sensitivity: respiratory and cutaneous manifestations. In E. Middleton, Jr., C. E. Reed, E. F. Ellis, N. F. Adkinson, and J. W. Yunginger, editors. Allergy, Principles and Practice. C. V. Mosby, St. Louis, MO. 1537-1554.
3. Bianco, S., M. Robuschi, and G. Petrini. 1987. Aspirin-induced tolerance in aspirin-asthma detected by a new challenge test. IRCS J. Med. Sci. 5:129.
4. Dahlén, B., and O. Zetterström. 1990. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 3:527-534.
5. Dahlén, B., M. Kumlin, D. J. Margolskee, C. Larsson, H. Blomqvist, V. C. Williams, O. Zetterström, and S.-E. Dahlén. 1993. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 6: 1018-1026.
6. Dahlén, B., L. O. Boréus, P. Anderson, R. Andersson, and O. Zetterström. 1994. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocations in aspirin-sensitive subjects. Allergy 49:43-49.
7. Gryglewski, R. J. 1979. Screening and assessment of the potency of antiinflammatory drugs in vitro. In J. R. Vane and S. H. Ferreira, editors. Antiinflammatory Drugs: Handbook of Experimental Pharmacology, Vol. 50. Springer-Verlag, Berlin. 1-43.
8. Mitchell, J. A., P. Akarasercenont, C. Thiemermann, R. J. Flower, and J. R. Vane. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenases. Proc. Natl. Acad. Sci. U.S.A. 90:11693-11697.
9. Peters-Golden, M., and T. G. Brock. 2000. Treatment of aspirin-intolerant asthma with antileukotrienes. Am. J. Respir. Crit. Care Med. 161 (Suppl. 1):S36-S40.
10. 4, and histamine in asthmatics. Am. Rev. Respir. Dis. 146:96-103.
11. 4 concentrations increase after ASA challenge in ASA-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143:1025-1029.
12. 4 during aspirin-induced asthma. J. Lab. Clin. Med. 119:48-51.
13. Christie, P. E., C. M. Smith, and T. H. Lee. 1991. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 144:957-958.
14. Israel E, A. R. Fischer, M. A. Rosenberg, C. M. Lilly, J. C. Callery, J. Shapiro, J. Cohn, P. Rubin, and J. M. Drazen. 1993. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. 148:1447-1451.
15. Nasser, S. M., G. S. Bell, S. Foster, K. E. Spruce, R. MacMillan, A. J. Williams, T. H. Lee, and J. P. Arm. 1994. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 49:749-756.
16. Yamamoto, H., M. Nagata, K. Kuramitsu, K. Tabe, H. Kiuchi, Y. Sakamoto, K. Yamamoto, and Y. Dohi. 1994, Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am. J. Respir. Crit. Care Med. 150:254-257.
17. Sakakibara, H., S. Suetsugu, T. Saga, M. Handa, M. Suzuki, T. Doizoe, M. Tsuda, T. Horiguchi, Y. Konishi, and H. Umeda. 1988. Bronchial hyperresponsiveness in aspirin induced asthma. J. Jpn. Thorac. Soc. 26:612-619.
18. 4 in subjects with ASA-induced asthma. Am. Rev. Respir. Dis. 140:148-153.
19. 4 in bronchial asthma, Eur. Respir. J. 5:693-699.
20. 2 following aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J. Allergy Clin. Immunol. 98: 421-432.
21. 4 in human urine. Clin. Exp. Allergy 25:467-479.
22. Widal, F., P. Abrami, and J. Lermoyez. 1922. Anaphylaxie et idiosyncrasie. Presse Med. 30:189-193.
23. Salén, E. B., and B. Amer. 1948. Some views on the aspirin-hypersensitive allergy group. Acta Allergol. 1:47-84.
24. Samter, M., and R. F. Beers. 1968. Intolerance to aspirin: clinical studies and considerations of its pathogenesis. Ann. Intern. Med. 68:975-983.
25. Sladek, K., and A. Szczeklik. 1993. Cysteinyl-leukotriene overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6:391-399.
26. Dahlén, B., D. J. Margolskee, O. Zetterström, and S.-E. Dahlén. 1993. Effect of the leukotriene-antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatics. Thorax 48:1205-1210.
27. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 67:17-28.
28. Snyder, D. W., R. E. Giles, R. A. Keith, Y. K. Yee, and R. D. Krell. 1987. The in vitro pharmacology of ICI-198,615: a novel, potent selective peptide leukotriene antagonist. J. Pharmacol. Exp. Ther. 243:548-556.
29. Björck, T., and S.-E. Dahlén. 1993. Leukotrienes and histamine are the exclusive mediators of IgE-dependent contractions of human bronchi in vitro. Pulm. Pharmacol. 6:87-96.
30. 4-induced bronchoconstriction in the human. Am. Rev. Respir. Dis. 144:617-621.
31. Taylor, I. K., K. M. O'Shaoughnessy, R. W. Fuller, and C. T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
32. Hui, K. P., and N. C. Barnes. 1991. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 337:1062-1063.
33. 4) receptor antagonist (MK-571) in asthma patients. Am. Rev. Respir. Dis. 146:358-363.
34. Israel, E., P. Rubin, J. P. Kemp, J. Grossman, W. Pierson, S. C. Siegel, D. Tinkelman, J. J. Murray, W. Busse, A. T. Segal, J. Fish, H. B. Kaiser, D. Ledford, S. Wenzel, R. Rosenthal, J. Cohn, C. Lanni, H. Pearlman, P. Karahalios, and J. M. Drazen. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 119:1059-1066.
35. Sebaldt, R. J., J. R. Sheller, J. A. Oates, L. J. Roberts, II, and G. A. FitzGerald. 1990. Inhibition of eicosanoid synthesis by glucocorticoids in humans. Proc. Natl. Acad. Sci. U.S.A. 87:6974-6978.
36. Manso, G., A. J. Baker, I. K. Taylor, and R. W. Fuller. 1992. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur. Respir. J. 5:712-716.
37. 4 excretion. Am. Rev. Respir. Dis. 147:1472-1476.
38. Dahlén, B., E. Nizankowska, A. Szczeklik, O. Zetterström, G. Bochenek, M. Kumlin, L. Mastalerz, G. Pinis, L. J. Swanson, T. I. Boodhoo, S. Wright, L. M. Dubé, and S.-E. Dahlén. 1998. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157:1187-1194.
39. Israel, E., J. Cohn, L. Dubé, and J. M. Drazen. 1996. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. J.A.M.A. 275:931-936.
40. Liu, M. C., L. M. Dubé, J. Lancaster, and the Zileuton Study Group. 1996. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicentertrial. J. Allergy Clin. Immunol. 98:859-871.
41. McGill, K. A., and W. W. Busse. 1996. Zileuton. Lancet 348:519-524.
42. Bisgaard, H., P. Olsson, and M. Bende. 1986. Effect of LTD4 on nasal mucosal blood flow, nasal airway resistance and nasal secretions in humans. Clin. Allergy 16:289-297.
43. 4 in grass polleninduced rhinitis. Am. Rev. Respir. Dis. 136:357-362.
44. Dworski, R., G. A. Fitzgerald, J. A. Oates, and J. R. Sheller. 1994. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med. 149:953-959.
45. Tamaoki, J., M. Kondo, N. Sakai, J. Nakata, H. Takemura, A. Nagai, T. Takizawa, and K. Konno. 1997. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am. J. Respir. Crit. Care Med. 155:1235-1240.